

**DECN ENTERS TODAY'S HIGH COURT HEARING WITH A GREAT DEAL OF ANTICIPATION THAT ITS LONG RUNNING LEGAL BATTLES WITH JOHNSON & JOHNSON ARE NEARING AN END**

**++ COMPANY'S CONFIDENCE GROWS ON THE BACK OF RECENT RULINGS IN THIS SAME COURT STRENGTHENING AN ALREADY STRONG DOE CASE WITH HUGE SETTLEMENT POTENTIAL ++**

LOS ANGELES, CA / October 2, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea, expected in late October 2019.

DECN announces today that in a few hours the company and its lawyers from the firm of Fox Rothschild, will argue the most important case in the company's history in front of a three judge panel in the Court of Appeals for the Federal Circuit (the patent dispute court). Opposing the company in front of the three judges will be lawyers hired for this matter by long time antagonist Johnson & Johnson. This hearing will mark the third time DECN and J&J did battle in this high court. DECN emerged totally victorious in the two previous cases heard in front of the three judge panels in this court, one time earning a Precedential ruling where new law was made.

Keith Berman, CEO of DECN commented, "Despite many delays and roadblocks, we have finally secured our day in court. The Appeals Court for the Federal Circuit is the highest court in the U.S. system, sitting just below the Supreme Court, that hears all disputes and matters involving patents. The three judge panel that will hear DECN's arguments and J&J's opposition, are all legal experts in the area of diabetic test strip technologies, and our past experience has shown that these judges are all no-nonsense jurists. Many of the misinformation the company has dealt with in the lower courts just do not hold purchase in the Federal Circuit."



Mr. Berman continued, “This marks our third visit to this court, all three resulting from various disputes with Johnson & Johnson. We were totally victorious in the two previous cases, the first time earning a Precedential Ruling (new law), and the second time earning a Mandate from the court that eliminated J&J’s foundational patent, and gave rise to the current case where DECN is looking to the courts to affirm that J&J has infringed on patents owned by DECN, thereby causing tens of millions, if not more, in damages.”



Mr. Berman concluded, “Another victory in the Federal Circuit Court will have a cascading effect on DECN, changing the nature of the company, dramatically changing the dynamics of DECN’s go forward business, especially with the proposed licensing of the company’s GenUltimate TBG technology. While the judge panel most likely will not rule from the bench at the conclusion of the oral arguments, the company and its supporters will most likely know where they stand by a careful listen of the questions posed by the judges as well as how well the lawyers for J&J respond to these questions. Today is definitely a “stay tuned” moment in the company’s history.”

#### **ABOUT DECISION DIAGNOSTICS CORP**

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a \$15+ billion at-home testing market. The company’s GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico.

#### **Forward-Looking Statements:**

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of October 1, 2019, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

#### **CONTACT INFORMATION:**

Decision Diagnostics Corp.  
Keith Berman (805) 446-2973

[info@decisiondiagnostics.co](mailto:info@decisiondiagnostics.co)  
[www.genultimate.com](http://www.genultimate.com)  
[www.genultimatebg.com](http://www.genultimatebg.com)  
[www.petsureteststrips.com](http://www.petsureteststrips.com)  
[www.pharmatechdirect.com](http://www.pharmatechdirect.com)

**SOURCE: Decision Diagnostics Corp.**